Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast biopsy & localization cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 44 | 2,592 | 50% |
| 2020 | 43 | 2,300 | 51% |
| 2021 | 37 |
Image-guided breast biopsy and marker/localization placement. Professional codes (what the surgeon bills): CPT 19081, 19083, 19085, 19281, 19283, 19285.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 51% of the cases CMS names in Oregon; 23 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 337 | 21,034+1.6%/yr | +1.6%/yr | 6.7 | 42% | 26,600 in 2030+4%/yr |
| Washington | 88 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Tumor & fibroid embolization | 6 | 355+8.7%/yr | +8.7%/yr | 0.91.5× | 30% | 460 in 2030+4.5%/yr |
| Tumor ablation |
Breast biopsy & localization in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
| ≈ 2,270 |
| – |
| 2026 est. | ≈ 2,340 | – |
| 2,299 |
| 53% |
| 2022 | 38 | 2,291 | 56% |
| 2023 | 36 | 2,256 | 58% |
| 2024 | 39 | 2,381 | 59% |
| 2025 from claims | – | 2,274 2,087–2,406 | 59% |
| 2026 forecast | – | 2,339 2,058–2,700 | 58% |
| 2027 forecast | – | 2,362 2,019–2,814 | 58% |
| 2028 forecast | – | 2,384 1,989–2,919 | 58% |
| 2029 forecast | – | 2,407 1,966–3,018 | 58% |
| 2030 forecast | – | 2,430 1,946–3,113 | 58% |
In 2025, 66% hospital outpatient, 34% office. The share outside the hospital has moved +7 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 5,486−3%/yr |
| −3%/yr |
| 7.6 |
| 47% |
| 5,580 in 2030+0.3%/yr |
| Arizona | 73 | 4,473−1.9%/yr | −1.9%/yr | 6.4 | 70% | 4,560 in 2030+0.3%/yr |
| Colorado | 51 | 3,013−3.3%/yr | −3.3%/yr | 6.6 | 36% | 3,380 in 2030+1.9%/yr |
| Nevada | 22 | 1,149−6.4%/yr | −6.4%/yr | 4.3 | 53% | 1,270 in 2030+1.7%/yr |
| New Mexico | 18 | 1,102−4.4%/yr | −4.4%/yr | 5.1 | 61% | 1,100 in 20300%/yr |
| Utah | 20 | 1,028−3.6%/yr | −3.6%/yr | 5.0 | 9% | 990 in 2030−0.7%/yr |
| Idaho | 12 | 906−4.7%/yr | −4.7%/yr | 4.7 | 5% | 1,220 in 2030+5.1%/yr |
| Montana | 12 | 694−8%/yr | −8%/yr | 3.8 | 5% | 810 in 2030+2.7%/yr |
| Hawaii | 10 | 618−1.8%/yr | −1.8%/yr | 5.2 | 25% | 620 in 2030−0.1%/yr |
| Alaska | 5 | 464+1.2%/yr | +1.2%/yr | 3.9 | 27% | 500 in 2030+1.3%/yr |
| Wyoming | 7 | 456+3.2%/yr | +3.2%/yr | 4.3 | 50% | 540 in 2030+2.9%/yr |
| 0 |
| 120+0.7%/yr |
| +0.7%/yr |
| 0.31.1× |
| 0% |
| 140 in 2030+2.7%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Exact Sciences leads with 36% of company spending on these surgeons in 2025, −16 pts on 2024.
In 2025, 13 companies reported engagement with Oregon’s surgeons worth $61K in consulting, speaking, meals and travel tied to these products, about $1,555 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.